The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants (Q28254690)

1

0 references

Daniel M Aebersold

2

0 references

Laura S Schmidt

3

0 references

Deborah Stroka

4

0 references

Christine Heigl

5

0 references

Bruno Streit

6

0 references

Denise Stalder

7

0 references

Guenther Gruber

8

0 references

Congxin Liang

9

0 references

Anthony R Howlett

10

0 references

Daniel Candinas

11

0 references

Richard H Greiner

12

0 references

Kenneth E Lipson

13

0 references

Yitzhak Zimmer

Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth

14

0 references

language of work or name

English

0 references

publication date

8 July 2004

0 references

published in

Oncogene

0 references

volume

23

0 references

issue

31

0 references

page(s)

5387-93

0 references

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207691

Dysregulation of Met receptor tyrosine kinase activity in invasive tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207691

Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207691

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207691

The mutationally activated Met receptor mediates motility and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207691

Activating mutations for the met tyrosine kinase receptor in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207691

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207691

Receptor tyrosine kinases as therapeutic targets: the model of the MET oncogene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207691

Karyotypic analysis of gastric carcinoma cell lines carrying an amplified c-met oncogene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207691

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207691

Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207691

Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207691

7 January 2021

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207691

7 January 2021

Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207691

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207691

7 January 2021

Different point mutations in the met oncogene elicit distinct biological properties.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207691

7 January 2021

A novel germ line juxtamembrane Met mutation in human gastric cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207691

7 January 2021

Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207691

7 January 2021

Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: modeling studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207691

7 January 2021

Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207691

7 January 2021

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207691

7 January 2021

Novel mutations of the MET proto-oncogene in papillary renal carcinomas.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207691

7 January 2021

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207691

7 January 2021

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207691

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1207691

1 reference

Consolidated OpenCitations Corpus – April 2017

Dimensions Publication ID

4839391

1034669915

0 references

4839391

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference